Peringatan Keamanan

Intravenous LD50 in mouse, rat, and rabbit is 340 mg/kg, 520 mg/kg, and 600 mg/kg, respectively. Subcutaneous LD50 in mouse and rat is 1600 mg/kg and >1000 mg/kg, respectively. Oral LD50 in mouse and rat is >3000 mg/kg and >1000 mg/kg, respectively. Nephrotoxicity, ototoxicity and retinal toxicity have been reported following long-term administration for chronic iron overload.

Deferoxamine

DB00746

small molecule approved investigational

Deskripsi

Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

Struktur Molekul 2D

Berat 560.684
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Biphasic elimination pattern in healthy volunteers with a first rapid phase half life of 1 hour and a second slow phase half-life of 6 hours.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Deferoxamine is rapidly absorbed after intramuscular or subcutaneous administration, but only poorly absorbed from the gastrointestinal tract in the presence of intact mucosa.

Metabolisme

Deferoxamine is mainly metabolised in the plasma and hepatic metabolism is minimal. A number of metabolites have been isolated but not characterised. Some metabolites of deferoxamine, most notably the product of oxidative deamination, also chelate iron, and thus the antidotal effect of the drug appears unaffected by hepatic metabolism.

Rute Eliminasi

Deferoxamine mesylate is metabolized principally by plasma enzymes, but the pathways have not yet been defined. Some is also excreted in the feces via the bile.

Interaksi Obat

8 Data
Ascorbic acid The risk or severity of Cardiovascular Impairment can be increased when Ascorbic acid is combined with Deferoxamine.
Dehydroascorbic acid The risk or severity of Cardiovascular Impairment can be increased when Dehydroascorbic acid is combined with Deferoxamine.
Sodium ascorbate The risk or severity of Cardiovascular Impairment can be increased when Sodium ascorbate is combined with Deferoxamine.
Calcium ascorbate The risk or severity of Cardiovascular Impairment can be increased when Calcium ascorbate is combined with Deferoxamine.
Zinc ascorbate The risk or severity of Cardiovascular Impairment can be increased when Zinc ascorbate is combined with Deferoxamine.
Niacinamide ascorbate The risk or severity of Cardiovascular Impairment can be increased when Niacinamide ascorbate is combined with Deferoxamine.
Prochlorperazine The risk or severity of adverse effects can be increased when Deferoxamine is combined with Prochlorperazine.
Technetium Tc-99m oxidronate Deferoxamine may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.

Target Protein

Iron
Aluminum
Amyloid-beta precursor protein APP

Referensi & Sumber

Synthesis reference: Zoltan Konyari, Vilmos Keri, Antal Kovacs, Sandor Horkay, Laszlo Eszenyi, Janos Erdelyi, Ilona Himesi, Gyorgy Toth, Janos Balint, SzilaJudit, Ferenc Vinczi, Csaba Szabo, Nelli Sas, "Process for the preparation of high-purity deferoxamine salts." U.S. Patent US5374771, issued July, 1965.
Link

Contoh Produk & Brand

Produk: 26 • International brands: 1
Produk
  • Deferoxamine
    Injection, powder, lyophilized, for solution • 95 mg/1mL • Intramuscular; Intravenous; Subcutaneous • US • Generic • Approved
  • Deferoxamine
    Injection, powder, lyophilized, for solution • 95 mg/1mL • Intramuscular; Intravenous; Subcutaneous • US • Generic • Approved
  • Deferoxamine Mesylate
    Injection, powder, lyophilized, for solution • 500 mg/5mL • Intramuscular; Intravenous; Subcutaneous • US • Generic • Approved
  • Deferoxamine Mesylate
    Injection, powder, lyophilized, for solution • 2 g/20mL • Intramuscular; Intravenous; Subcutaneous • US • Generic • Approved
  • Deferoxamine mesylate
    Injection, powder, lyophilized, for solution • 500 mg/5.3mL • Intramuscular; Intravenous; Subcutaneous • US • Generic • Approved
  • Deferoxamine mesylate
    Injection, powder, lyophilized, for solution • 2 g/21.1mL • Intramuscular; Intravenous; Subcutaneous • US • Generic • Approved
  • Deferoxamine mesylate
    Injection, powder, lyophilized, for solution • 500 mg/1 • Intramuscular; Intravenous; Subcutaneous • US • Generic • Approved
  • Deferoxamine mesylate
    Injection, powder, lyophilized, for solution • 2 g/1 • Intramuscular; Intravenous; Subcutaneous • US • Generic • Approved
Menampilkan 8 dari 26 produk.
International Brands
  • Desferin — Novartis

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul